Super giant, betting on AI pharmaceuticals
No one wants to miss the opportunity.
Time：
2026-06-15 17:22
Author：
xieyijun
In 2026, the first batch of answers for CAR-T in vivo will be submitted
Speaking with data, the track is finally validated.
Time：
2026-06-15 08:51
Author：
xieyijun
Hong Kong Stocks' Mid-Term Exam: Value Crushing
Valuation low point and innovation high point
Time：
2026-06-14 09:35
Author：
xieyijun
A Major Power in New Drugs – It's Time to Have Its Own Voice.
Strategic Reflections on China's Pharmaceutical Voice
Time：
2026-06-11 19:08
Author：
xieyijun
The Race for the "Third Place" in Weight-Loss Drugs
Time：
2026-06-10 18:12
Author：
xieyijun
CPIC 2026 | Full Agenda Unveiled: China-Japan Cooperation Session
Leveraging the Japanese Market to Drive Globalization Strategy
Time：
2026-06-08 10:48
Author：
xieyijun
Dense Blockbusters, Intense Activity: Oligonucleotides Enter the Harvest Period
Exclusive Interview with Li Hao, Preclinical CMO at Convalife (Kanglonghua)
Time：
2026-06-07 17:20
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务